This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

48/100

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Drug development

Topic: Brain proteins, microglia and lab models

Treatments for neurodegenerative disorders remain rare, but recent FDA approvals, such as lecanemab and aducanumab for Alzheimer disease (MIM: 607822), highlight the importance of the underlying biological mechanisms in driving discovery and creating disease modifying therapies. The global population is aging, driving an urgent need for therapeutics that stop disease progression and eliminate symptoms. In this study, we create an open framework and resource for evidence-based identification of therapeutic targets for neurodegenerative disease.

Key findings

The global population is aging, driving an urgent need for therapeutics that stop disease progression and eliminate symptoms.
In this study, we create an open framework and resource for evidence-based identification of therapeutic targets for neurodegenerative disease.
We use summary-data-based Mendelian randomization to identify genetic targets for drug discovery and repurposing.
In parallel, we provide mechanistic insights into disease processes and potential network-level consequences of gene-based therapeutics.

Why it matters

This study created an open multi-omic resource using summary-data-based Mendelian randomization to identify genetic targets for drug discovery and repurposing for neurodegenerative diseases. It provides a framework for identifying targets rather than reporting a treatment that cures or prevents Alzheimer's disease.

New to this subject? Start with our plain-English guide: Treatments →

Study details

Effect size69.8%
Evidence strengthLow

How this study scored 48/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (American journal of human genetics)
Journal's citation record	3 / 4	The American Journal of Human Genetics: journal h-index 385 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2024 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	2 / 3	Effect reported as a number, without an interval or test
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	3 / 7	Cited 19 times (OpenAlex, 2026-10-10)
Citations per year	2 / 5	4.8 citations a year over 4 year(s) since 2024
Impact for its field and year	3 / 6	Cited 3.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	2 / 4	Cited 16 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Hampton L. Leonard: h-index 37 (OpenAlex, whole career)
Institution's track record	3 / 3	National Institutes of Health: institution h-index 2,723 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 7 institution(s) in 3 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 38181731)
Free to read	2 / 2	Free to read
Total	48 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Alvarado, C. X., Makarious, M. B., Weller, C. A., Vitale, D., Koretsky, M. J., Bandres-Ciga, S., et al. (2024). omicSynth: An open multi-omic community resource for identifying druggable targets across neurodegenerative diseases. American journal of human genetics. https://doi.org/10.1016/j.ajhg.2023.12.006

Vancouver

Alvarado CX, Makarious MB, Weller CA, Vitale D, Koretsky MJ, Bandres-Ciga S, et al. omicSynth: An open multi-omic community resource for identifying druggable targets across neurodegenerative diseases. American journal of human genetics. 2024. doi:10.1016/j.ajhg.2023.12.006. PMID: 38181731.

BibTeX

@article{alvarado2024-38181731,
  author  = {Alvarado, C. X. and Makarious, M. B. and Weller, C. A. and Vitale, D. and Koretsky, M. J. and Bandres-Ciga, S. and Iwaki, H. and Levine, K. and others},
  title   = {{omicSynth: An open multi-omic community resource for identifying druggable targets across neurodegenerative diseases}},
  journal = {American journal of human genetics},
  year    = {2024},
  doi     = {10.1016/j.ajhg.2023.12.006},
  pmid    = {38181731},
  url     = {https://doi.org/10.1016/j.ajhg.2023.12.006}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Drug development

Also in Drug development

79 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.

Similar studies

More on Drug development

See all studies in Drug development →